Insulin product classification based on where insulin is manufactured and place of corporate headquarters
| Entity for whom insulin is made (by corporate headquarters) | ||
|---|---|---|
| Place of manufacture | Indian (eg, Biocon, Wockhardt, Lupin) | Foreign (eg, Eli Lilly, Novo Nordisk, Sanofi Aventis) |
| India | Domestically manufactured, for Indian company (n=16) | Domestically manufactured, for foreign company (n=87) |
| Human insulin=100.0% | Human insulin=100.0% | |
| Insulin analogues=0.0% | Insulin analogues=0.0% | |
| Overseas | Imported, for Indian company (n=2) | Imported, for foreign company (n=69) |
| Human insulin=0.0% | Human insulin=44.9% | |
| Insulin analogues=100.0% | Insulin analogues=55.1% | |
Numbers ‘n’ in parentheses are the number of all products, irrespective of dosage strength and delivery vehicle, found for a particular classification (eg, 87 insulins—including duplicates—made in India for a foreign company).
Percentages are the fraction of products in any classification relegated to human and analogue insulins (eg, all 103 insulins (16+87)—including duplicates—made in India for Indian and foreign companies were human, not analogue insulin).